LivaNova (LIVN) to Release Quarterly Earnings on Tuesday

LivaNova (NASDAQ:LIVN - Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of $0.80 per share and revenue of $324.11 million for the quarter. Parties interested in participating in the company's conference call can do so using this link.

LivaNova Stock Down 1.1 %

NASDAQ:LIVN traded down $0.55 on Friday, hitting $47.44. The stock had a trading volume of 493,509 shares, compared to its average volume of 451,071. The business's fifty day moving average is $48.04 and its 200 day moving average is $49.53. The company has a market cap of $2.58 billion, a PE ratio of 112.95 and a beta of 1.00. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. LivaNova has a 52 week low of $43.15 and a 52 week high of $64.47.

Analyst Ratings Changes

LIVN has been the topic of several recent research reports. Robert W. Baird increased their price target on LivaNova from $66.00 to $72.00 and gave the stock an "outperform" rating in a report on Thursday, October 31st. Needham & Company LLC reiterated a "buy" rating and issued a $75.00 price target on shares of LivaNova in a report on Tuesday, January 28th. StockNews.com upgraded LivaNova from a "buy" rating to a "strong-buy" rating in a report on Friday, February 14th. Finally, Mizuho lowered their price objective on LivaNova from $80.00 to $70.00 and set an "outperform" rating for the company in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $69.17.

Insider Transactions at LivaNova

In related news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the sale, the director now directly owns 7,522 shares of the company's stock, valued at approximately $383,546.78. This trade represents a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.27% of the company's stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.